Stay updated on Pembrolizumab vs Docetaxel in NSCLC: Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab vs Docetaxel in NSCLC: Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab vs Docetaxel in NSCLC: Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    8 days ago
    No Change Detected
  3. Check
    15 days ago
    No Change Detected
  4. Check
    22 days ago
    Change Detected
    Summary
    Revision: v3.5.0 added and v3.4.3 removed.
    Difference
    0.1%
    Check dated 2026-03-18T17:45:44.000Z thumbnail image
  5. Check
    29 days ago
    Change Detected
    Summary
    Revision updated from v3.4.2 to v3.4.3; no changes to study details or other visible content.
    Difference
    0.1%
    Check dated 2026-03-11T14:43:15.000Z thumbnail image
  6. Check
    58 days ago
    Change Detected
    Summary
    Added Revision: v3.4.2 and removed the previous funding-notice banner and Revision: v3.4.1 banner; changes affect only site-wide notices rather than the study page content.
    Difference
    0.4%
    Check dated 2026-02-11T02:20:04.000Z thumbnail image
  7. Check
    65 days ago
    Change Detected
    Summary
    Added a global funding-status notice and a page version update (v3.4.1); these changes do not alter the study content or its core functionality. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2026-02-03T23:01:09.000Z thumbnail image
  8. Check
    72 days ago
    Change Detected
    Summary
    Added a glossary toggle and updated the QC-related label to 'Last Update Submitted that Met QC Criteria' and added 'No FEAR Act Data' with the site revision 'v3.4.0'. Removed the older 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and 'Revision: v3.3.4'.
    Difference
    0.2%
    Check dated 2026-01-27T21:26:55.000Z thumbnail image
  9. Check
    108 days ago
    Change Detected
    Summary
    Footer-level revision notices were updated: a new 'Revision: v3.3.3' was added and the 'HHS Vulnerability Disclosure' and 'Revision: v3.3.2' items were removed. No study content or results sections were changed.
    Difference
    0.1%
    Check dated 2025-12-22T22:46:10.000Z thumbnail image

Stay in the know with updates to Pembrolizumab vs Docetaxel in NSCLC: Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab vs Docetaxel in NSCLC: Clinical Trial page.